• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Immunic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    6/27/25 5:15:46 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMUX alert in real time by email
    false 0001280776 0001280776 2025-06-27 2025-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 27, 2025

     

    IMMUNIC, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-36201 56-2358443
    (State or other jurisdiction
    of incorporation)
    (Commission File Number) (IRS Employer Identification No.)

     

    1200 Avenue of the Americas, Suite 200

    New York, NY 10036

    USA

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (332) 255-9818 

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of exchange on which registered
    Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Rule or Standard; Transfer of Listing. 

     

    On June 27, 2025, Immunic, Inc. (the "Company") received a written notification (the “Notice Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until December 24, 2025 (the “Initial Compliance Period”), to regain compliance with the minimum bid price requirement. If we do not regain compliance by the end of the Initial Compliance Period, we may apply for an additional compliance period as provided for in the Notice Letter. Nasdaq’s determination of whether we qualify for an additional compliance period will depend on whether we will meet the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and a written notice of our intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary.

     

    The Notice Letter has no immediate effect on the listing of our common stock on The Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we can regain compliance if the closing bid price of our common stock is at least $1.00 for a minimum of 10 consecutive business days. In the event that we do not regain compliance with Listing Rule 5450(a)(1) prior to the expiration of the Initial Compliance Period (or additional compliance period, if applicable), we will receive written notification that our securities are subject to delisting.

     

    The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the minimum bid price requirement. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or that the Company will otherwise remain in compliance with the other listing standards for the Nasdaq Stock Market.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

    Dated: June 27, 2025 Immunic, Inc.
         
      By: /s/ Daniel Vitt
        Daniel Vitt
        Chief Executive Officer

     

     

     

     

    Get the next $IMUX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMUX

    DatePrice TargetRatingAnalyst
    3/25/2025Outperform
    William Blair
    11/25/2024$10.00Buy
    H.C. Wainwright
    9/9/2024$5.00Outperform
    Leerink Partners
    8/27/2024$6.00Buy
    B. Riley Securities
    10/21/2022$5.00Outperform → Mkt Perform
    SVB Leerink
    9/19/2022$26.00Buy
    H.C. Wainwright
    9/7/2021$40.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMUX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

      – At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years – NEW YORK, June 24, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new long-term open-label extension (OLE) data from its phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838)

      6/24/25 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

      – Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential – – New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes – NEW YORK, June 5, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a

      6/5/25 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

      NEW YORK, June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The Pre-Funded Warrants are immediately exercisa

      6/3/25 4:01:00 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Immunic

      William Blair initiated coverage of Immunic with a rating of Outperform

      3/25/25 8:27:26 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Immunic with a new price target

      H.C. Wainwright initiated coverage of Immunic with a rating of Buy and set a new price target of $10.00

      11/25/24 7:45:37 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Immunic with a new price target

      Leerink Partners resumed coverage of Immunic with a rating of Outperform and set a new price target of $5.00

      9/9/24 7:37:13 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    SEC Filings

    See more
    • Immunic Inc. filed SEC Form 8-K: Leadership Update

      8-K - IMMUNIC, INC. (0001280776) (Filer)

      7/11/25 5:01:03 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - IMMUNIC, INC. (0001280776) (Filer)

      6/27/25 5:15:46 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IMMUNIC, INC. (0001280776) (Filer)

      6/4/25 4:07:37 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: President and COO Tardio Jason bought $9,884 worth of shares (12,512 units at $0.79) (SEC Form 4)

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:16:19 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Chief Financial Officer Whaley Glenn

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:16:01 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CEO and Director Vitt Daniel bought $11,550 worth of shares (15,000 units at $0.77), increasing direct ownership by 107% to 29,000 units (SEC Form 4)

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:15:45 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: President and COO Tardio Jason bought $9,884 worth of shares (12,512 units at $0.79) (SEC Form 4)

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:16:19 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CEO and Director Vitt Daniel bought $11,550 worth of shares (15,000 units at $0.77), increasing direct ownership by 107% to 29,000 units (SEC Form 4)

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:15:45 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Nash Duane bought $16,694 worth of shares (20,000 units at $0.83), increasing direct ownership by 125% to 36,032 units (SEC Form 4)

      4 - IMMUNIC, INC. (0001280776) (Issuer)

      6/16/25 5:00:19 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunic Highlights 2024 Accomplishments and Upcoming Milestones

      – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,

      1/7/25 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

      – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea

      7/24/24 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Appoints Jason Tardio as Chief Operating Officer and President

      – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in

      7/9/24 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunic Inc.

      SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

      11/14/24 5:33:45 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunic Inc.

      SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

      11/14/24 12:30:35 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunic Inc.

      SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

      11/14/24 6:58:13 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Financials

    Live finance-specific insights

    See more
    • Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

      – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr

      10/9/23 4:01:00 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

      – Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro

      5/4/23 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

      – 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi

      4/5/23 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care